{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T22:22:06Z","timestamp":1780352526316,"version":"3.54.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Telemonitoring could be an alternative for standard face-to-face consultations. In adults with inflammatory bowel disease (IBD), telemonitoring has been associated with improved quality of life (QoL) and reduced costs. We aimed to assess whether telemonitoring of adolescents with IBD is non-inferior to standard care in controlling disease activity. We searched Medline and Embase up to June 15, 2025, for randomized trials comparing the effect of telemonitoring and standard care on disease activity in adolescents with IBD. Secondary outcomes were QoL, costs, patient satisfaction, patient adherence, face-to-face contacts, and emergency room attendances or hospitalizations. Risk of bias and certainty of evidence were assessed using the Risk of Bias 2 tool and GRADE, respectively. Data was synthesized and reported in accordance with the Synthesis Without Meta-analysis (SWiM) reporting guideline and the Cochrane Handbook. Three studies (309 patients) were identified. Risk of bias was judged \u201chigh\u201d for one study and as \u201csome concerns\u201d for the remaining two studies. We found that telemonitoring may not worsen disease activity (low-certainty evidence) and may result in little to no improvement in QoL (low-certainty evidence) compared to standard care. Telemonitoring likely results in a slight cost reduction (moderate- certainty evidence). <jats:italic>Conclusion<\/jats:italic>: Telemonitoring may be non-inferior to standard care in controlling disease activity for adolescents with IBD. \n<jats:table-wrap>\n              <jats:table>\n                <jats:tbody>\n                  <jats:tr>\n                    <jats:td align=\"left\">\n                      <jats:bold>What is Known:<\/jats:bold>\u2022 <jats:italic>Studies comparing telemonitoring with standard follow-up in adults with inflammatory bowel disease (IBD) did not find a difference in disease activity or the occurrence of flares between these strategies.<\/jats:italic>\u2022 <jats:italic>Telemonitoring could improve quality of life and reduce costs and health care utilization in adults.<\/jats:italic>\n                    <\/jats:td>\n                  <\/jats:tr>\n                  <jats:tr>\n                    <jats:td align=\"left\">\n                      <jats:bold>What is New:<\/jats:bold>\u2022 <jats:italic>This systematic review exclusively reviews the effect of telemonitoring on adolescents with IBD.<\/jats:italic>\u2022 <jats:italic>Based on limited evidence, following adolescents with IBD with telemonitoring appears to be safe and may reduce the number of outpatient visits and societal costs.<\/jats:italic>\n                    <\/jats:td>\n                  <\/jats:tr>\n                <\/jats:tbody>\n              <\/jats:table>\n            <\/jats:table-wrap>\n          <\/jats:p>","DOI":"10.1007\/s00431-025-06341-z","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T21:34:04Z","timestamp":1754429644000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Telemonitoring in adolescents with inflammatory bowel disease: a systematic review"],"prefix":"10.1007","volume":"184","author":[{"given":"Mike P. T.","family":"Kusters","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marleen","family":"Bouhuys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin W. M.","family":"Vernooij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linde F.","family":"Huis in \u2019t Veld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan E.","family":"van Limbergen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bada","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick F.","family":"van Rheenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,5]]},"reference":[{"key":"6341_CR1","doi-asserted-by":"crossref","unstructured":"Dijkstra A, Heida A, van Rheenen PF (2019) Exploring the challenges of implementing a web-based telemonitoring strategy for teenagers with inflammatory bowel disease: empirical case study. J Med Internet Res 21:e11761","DOI":"10.2196\/11761"},{"key":"6341_CR2","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1136\/gutjnl-2020-321244","volume":"69","author":"NA Kennedy","year":"2020","unstructured":"Kennedy NA, Jones GR, Lamb CA, Appleby R, Arnott I, Beattie RM, Bloom S et al (2020) British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic. Gut 69:984\u2013990","journal-title":"Gut"},{"key":"6341_CR3","doi-asserted-by":"crossref","unstructured":"Gordon M, Sinopoulou V, Lakunina S, Gjuladin-Hellon T, Bracewell K, Akobeng AK (2023) Remote care through telehealth for people with inflammatory bowel disease. Cochrane Database Syst Rev 5:Cd014821","DOI":"10.1002\/14651858.CD014821.pub2"},{"key":"6341_CR4","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/nur.22091","volume":"44","author":"SP Davis","year":"2021","unstructured":"Davis SP, Ross MSH, Adatorwovor R, Wei H (2021) Telehealth and mobile health interventions in adults with inflammatory bowel disease: a mixed-methods systematic review. Res Nurs Health 44:155\u2013172","journal-title":"Res Nurs Health"},{"key":"6341_CR5","doi-asserted-by":"publisher","first-page":"829","DOI":"10.3748\/wjg.v20.i3.829","volume":"20","author":"VW Huang","year":"2014","unstructured":"Huang VW, Reich KM, Fedorak RN (2014) Distance management of inflammatory bowel disease: systematic review and meta-analysis. World J Gastroenterol 20:829\u2013842","journal-title":"World J Gastroenterol"},{"key":"6341_CR6","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3109\/00365521.2013.865259","volume":"49","author":"SR Knowles","year":"2014","unstructured":"Knowles SR, Mikocka-Walus A (2014) Utilization and efficacy of internet-based eHealth technology in gastroenterology: a systematic review. Scand J Gastroenterol 49:387\u2013408","journal-title":"Scand J Gastroenterol"},{"key":"6341_CR7","doi-asserted-by":"publisher","first-page":"78","DOI":"10.14309\/ajg.0000000000001545","volume":"117","author":"NH Nguyen","year":"2022","unstructured":"Nguyen NH, Martinez I, Atreja A, Sitapati AM, Sandborn WJ, Ohno-Machado L, Singh S (2022) Digital health technologies for remote monitoring and management of inflammatory bowel disease: a systematic review. Am J Gastroenterol 117:78\u201397","journal-title":"Am J Gastroenterol"},{"key":"6341_CR8","doi-asserted-by":"publisher","first-page":"e28978","DOI":"10.2196\/28978","volume":"24","author":"L Pang","year":"2022","unstructured":"Pang L, Liu H, Liu Z, Tan J, Zhou LY, Qiu Y, Lin X, He J, Li X, Lin S, Ghosh S, Mao R, Chen M (2022) Role of telemedicine in inflammatory bowel disease: systematic review and meta-analysis of randomized controlled trials. J Med Internet Res 24:e28978","journal-title":"J Med Internet Res"},{"key":"6341_CR9","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jadohealth.2015.04.012","volume":"57","author":"R Cole","year":"2015","unstructured":"Cole R, Ashok D, Razack A, Azaz A, Sebastian S (2015) Evaluation of outcomes in adolescent inflammatory bowel disease patients following transfer from pediatric to adult health care services: case for transition. J Adolesc Health 57:212\u2013217","journal-title":"J Adolesc Health"},{"key":"6341_CR10","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898","journal-title":"BMJ"},{"key":"6341_CR11","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Sch\u00fcnemann HJ (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336:924\u2013926","journal-title":"BMJ"},{"key":"6341_CR12","doi-asserted-by":"publisher","first-page":"l6890","DOI":"10.1136\/bmj.l6890","volume":"368","author":"M Campbell","year":"2020","unstructured":"Campbell M, McKenzie JE, Sowden A, Katikireddi SV, Brennan SE, Ellis S, Hartmann-Boyce J, Ryan R, Shepperd S, Thomas J, Welch V, Thomson H (2020) Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline. BMJ 368:l6890","journal-title":"BMJ"},{"key":"6341_CR13","unstructured":"McKenzie JE, Brennan SE (2023) Synthesizing and presenting findings using other methods. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds) Cochrane Handbook for Systematic Reviews of Interventions version 64 (updated August 2023). https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current\/chapter-12. Accessed 14 June 2025"},{"key":"6341_CR14","volume-title":"Review Manager 5","author":"The Cochrane Collaboration","year":"2020","unstructured":"The Cochrane Collaboration (2020) Review Manager 5. The Cochrane Collaboration, Copenhagen"},{"key":"6341_CR15","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T (2014) Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol 14:135","journal-title":"BMC Med Res Methodol"},{"key":"6341_CR16","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1093\/ecco-jcc\/jjx169","volume":"12","author":"A Heida","year":"2018","unstructured":"Heida A, Dijkstra A, Muller Kobold A, Rossen JW, Kindermann A, Kokke F, de Meij T, Norbruis O, Weersma RK, Wessels M, Hummel T, Escher J, van Wering H, Hendriks D, Mearin L, Groen H, Verkade HJ, van Rheenen PF (2018) Efficacy of home telemonitoring versus conventional follow-up: a randomized controlled trial among teenagers with inflammatory bowel disease. J Crohns Colitis 12:432\u2013441","journal-title":"J Crohns Colitis"},{"key":"6341_CR17","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.ebiom.2015.08.011","volume":"2","author":"AK Akobeng","year":"2015","unstructured":"Akobeng AK, O\u2019Leary N, Vail A, Brown N, Widiatmoko D, Fagbemi A, Thomas AG (2015) Telephone consultation as a substitute for routine out-patient face-to-face consultation for children with inflammatory bowel disease: randomised controlled trial and economic evaluation. EBioMedicine 2:1251\u20131256","journal-title":"EBioMedicine"},{"key":"6341_CR18","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1097\/MIB.0000000000001170","volume":"23","author":"K Carlsen","year":"2017","unstructured":"Carlsen K, Jakobsen C, Houen G, Kallemose T, Paerregaard A, Riis LB, Munkholm P, Wewer V (2017) Self-managed eHealth disease monitoring in children and adolescents with inflammatory bowel disease: a randomized controlled trial. Inflamm Bowel Dis 23:357\u2013365","journal-title":"Inflamm Bowel Dis"},{"key":"6341_CR19","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"key":"6341_CR20","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1023\/A:1014455702807","volume":"11","author":"HJ Loonen","year":"2002","unstructured":"Loonen HJ, Grootenhuis MA, Last BF, de Haan RJ, Bouquet J, Derkx BH (2002) Measuring quality of life in children with inflammatory bowel disease: the impact-II (NL). Qual Life Res 11:47\u201356","journal-title":"Qual Life Res"},{"key":"6341_CR21","first-page":"557","volume":"35","author":"A Otley","year":"2002","unstructured":"Otley A, Smith C, Nicholas D, Munk M, Avolio J, Sherman PM, Griffiths AM (2002) The IMPACT questionnaire: a valid measure of health-related quality of life in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 35:557\u2013563","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"6341_CR22","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1097\/MPG.0b013e3182165d10","volume":"53","author":"CA Ogden","year":"2011","unstructured":"Ogden CA, Akobeng AK, Abbott J, Aggett P, Sood MR, Thomas AG (2011) Validation of an instrument to measure quality of life in British children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 53:280\u2013286","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"6341_CR23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/jrsm.1458","volume":"12","author":"MH Boon","year":"2021","unstructured":"Boon MH, Thomson H (2021) The effect direction plot revisited: Application of the 2019 Cochrane Handbook guidance on alternative synthesis methods. Res Synth Methods 12:29\u201333","journal-title":"Res Synth Methods"},{"key":"6341_CR24","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (2023) Cochrane handbook for systematic reviews of interventions version 6.4. http:\/\/www.training.cochrane.org\/handbook. Accessed 14 June 2025"},{"key":"6341_CR25","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JAC (2011) The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343:d5928\u2013d5928","journal-title":"BMJ"},{"issue":"10","key":"6341_CR26","first-page":"1583","volume":"18","author":"L Fierens","year":"2024","unstructured":"Fierens L, Carney N, Novacek G, van der Woude CJ, Siegmund B, Casellas F, Borruel N et al (2024) A core outcome set for inflammatory bowel diseases: development and recommendations for implementation in clinical practice through an international multi-stakeholder consensus process. J Crohns Colitis 18(10):1583\u20131595","journal-title":"J Crohns Colitis."},{"key":"6341_CR27","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.dld.2020.12.011","volume":"53","author":"S Arrigo","year":"2021","unstructured":"Arrigo S, Alvisi P, Banzato C, Bramuzzo M, Celano R, Civitelli F, D\u2019Arcangelo G, Dilillo A, Dipasquale V, Felici E, Fuoti M, Gatti S, Knafelz D, Lionetti P, Mario F, Marseglia A, Martelossi S, Moretti C, Norsa L, Panceri R, Renzo S, Romano C, Romeo E, Strisciuglio C, Martinelli M (2021) Impact of COVID-19 pandemic on the management of paediatric inflammatory bowel disease: an Italian multicentre study on behalf of the SIGENP IBD Group. Dig Liver Dis 53:283\u2013288","journal-title":"Dig Liver Dis"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-025-06341-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00431-025-06341-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-025-06341-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T07:44:48Z","timestamp":1758008688000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00431-025-06341-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,5]]},"references-count":27,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["6341"],"URL":"https:\/\/doi.org\/10.1007\/s00431-025-06341-z","relation":{},"ISSN":["1432-1076"],"issn-type":[{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,5]]},"assertion":[{"value":"26 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Since this is a systematic review of published studies, ethical approval by an ethics committee was not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"PvR was the PI of one of the included studies in this systematic review (Heida et al.). PvR was not involved in the risk of bias assessment or data synthesis of this study. PvR receives support in kind from B\u00dcHLMANN Laboratories AG (Sch\u00f6nenbuch, Switzerland) for an ongoing trial. All other authors declare no competing interests. The other authors have no conflicts of interest to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"531"}}